House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Neonatology

Surfactant Therapy in Neonates

IAP / NNF · 2026 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

The IAP–NNF quick-reference chapter prioritizes early rescue surfactant after CPAP stabilization, appropriate administration by a trained neonatal team and rapid adjustment of oxygen and ventilatory support after response. Redosing requires persistent respiratory need and exclusion of alternative causes.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Select early rescue treatment and ensure capability

  • For preterm infants below 34 weeks with established RDS on CPAP, the executive summary recommends early rescue surfactant when FiO2 exceeds 30% with PEEP at least 6 cmH2O to maintain SpO2 at least 91%. Both oxygen and pressure criteria apply. [1]
  • Prefer early rescue within 2 hours rather than delayed treatment. Stabilize spontaneously breathing infants below 28 weeks on CPAP first; do not give routine prophylaxis. An infant intubated in the delivery room for severe RDS may receive prophylactic surfactant. [1]
  • For severe RDS at 34–38 weeks failing CPAP, the indication table uses PEEP at least 7 and FiO2 above 40%, with early rescue within 2 hours. [1]
  • Do not administer when adequate monitoring, trained intubation personnel, CPAP or backup ventilation are unavailable. A physician competent in laryngoscopy must be present, and LISA requires specific training. [1]
  • Control significant pulmonary bleeding, stabilize severe cardiovascular instability and treat an active air leak first. Routine surfactant is not indicated for congenital diaphragmatic hernia or suspected pulmonary hypoplasia and may be harmful; coagulopathy increases bleeding risk. [1]

Use the appropriate method and preparation

  • Prefer LISA/MIST for spontaneously breathing infants below 34 weeks receiving CPAP. Use INSURE when LISA is not feasible or when intubation is required. [1]
  • Poractant alfa is the preferred preparation at an initial 200 mg/kg (2.5 mL/kg); repeat doses are 100 mg/kg (1.25 mL/kg), separated by at least 12 hours, with a maximum of 3 total doses. [1]
  • The table lists beractant at 100 mg/kg (4 mL/kg) for initial and repeat doses, at least 6 hours apart, maximum 4 total doses. Bovine lipid extract is listed at 135 mg/kg (5 mL/kg) on the same minimum interval and maximum total dose count. [1]
  • Confirm RDS clinically; chest radiography or lung ultrasound can assist but are not essential. Keep the infant normothermic and warm the surfactant vial in the palm before administration. [1]
  • During LISA, maintain CPAP and give surfactant slowly over 2–3 minutes rather than a rapid bolus. Keep the infant supine with the head midline, pausing for desaturation or bradycardia; provide brief positive-pressure ventilation and stimulation, then resume once stable. [1]
  • Routine sedation or analgesia for LISA is not recommended. Prefer non-pharmacological measures; reserve fentanyl for an extremely vigorous infant after those measures fail, or when the first LISA attempt fails because of agitation. Atropine is not routine. [1]
  • For INSURE, confirm tracheal placement, give surfactant through the tube in aliquots with gentle positive-pressure ventilation, and extubate once stable within 30–60 minutes to immediate CPAP or non-invasive positive-pressure ventilation. [1]

Reassess persistent respiratory need before another dose

  • Consider a repeat dose when FiO2 remains above 40% together with PEEP/MAP at least 7 cmH2O on invasive or non-invasive support. First exclude pneumothorax, tube malposition, patent ductus arteriosus and sepsis. [1]
  • A lower redosing threshold, FiO2 above 30% on any ventilation, may be considered in very immature infants with concomitant perinatal asphyxia or sepsis. [1]
  • The chapter does not recommend surfactant for outborn preterm infants below 34 weeks who present after 72 hours, regardless of previous therapy. [1]

Monitor response and manage complications

  • Avoid routine endotracheal or airway suction for 4–6 hours after dosing. Reduce FiO2 first within 5–10 minutes of improved saturation, then reduce ventilatory pressures after stabilization, while continuing vital monitoring. [1]
  • For transient hypoxia or bradycardia, pause administration, provide brief ventilation and stimulation, and resume once stable. A blocked endotracheal tube requires airway clearance and possibly reintubation; this emergency is distinct from routine postdose suction avoidance. [1]
  • Recognize pneumothorax promptly and manage it with the indicated decompression and drainage pathway. Postdose overoxygenation requires immediate FiO2 reduction and stepwise pressure reduction. [1]

Limitations and use

  • This is a neonatal-unit procedure summary, not a substitute for trained airway management or the complete unit protocol. The source expands MAP inconsistently; this summary retains the respiratory-support abbreviation without assigning an unsupported meaning. Unreadable graphical algorithm branches are not reconstructed. Routine avoidance of suction does not override the chapter’s emergency management of a blocked airway.
  • The general rescue threshold and the indication table for infants born before twenty-eight weeks are not identical: the latter gives FiO₂ at least 0.30–0.40 and rising despite adequate CPAP. The executive threshold must not be treated as the sole indication across all gestational groups.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Surfactant Therapy in Neonates

    Selected recommendation material consulted

Quick-reference guideline

Publication details

Issuing organisation
IAP / NNF
Resource type
Quick-reference guideline · House clinical summary
Source setting
India

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Select early rescue treatment and ensure capability
  • Use the appropriate method and preparation
  • Reassess persistent respiratory need before another dose
  • Monitor response and manage complications
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House